Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up

Experimental Hematology
Tohru NakagawaTadao Kakizoe

Abstract

The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen (RIST) for interferon-alpha-refractory metastatic renal cell carcinoma (RCC). Of 26 patients referred to the National Cancer Center Hospital for possible RIST between June 2000 and April 2002, an HLA-identical relative was identified for 12 patients. Nine patients underwent RIST. The conditioning regimen consisted of fludarabine 180 mg/m2 or cladribine 0.66 mg/kg, plus busulfan 8 mg/kg and rabbit antithymocyte globulin 5 mg/kg. Graft-vs-host disease (GVHD) prophylaxis was cyclosporine alone. All patients achieved engraftment without grade III to IV nonhematologic regimen-related toxicity. All patients achieved complete donor-type chimerism without donor lymphocyte infusion by day 60. Four patients developed acute GVHD, and four developed chronic GVHD. One patient (11%) achieved partial response. As of July 2003, six patients were alive at median follow-up of 681 days. The actuarial overall survival rate was 89% at 1 year and 74% at 2 years. The overall survival rate tended to be higher in the 12 patients with a matched donor than in the other 14 patients without a matc...Continue Reading

References

Jan 23, 2002·Bone Marrow Transplantation·H ZetterquistO Ringdén
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniNicholas J Vogelzang
Jun 4, 2002·Nature Medicine·Takanori TeshimaJames L M Ferrara
Dec 17, 2003·Bone Marrow Transplantation·A HoriY Takaue

❮ Previous
Next ❯

Citations

Apr 10, 2008·Nature Clinical Practice. Oncology·Taner DemirerUNKNOWN EBMT Solid Tumors Working Party
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Jan 23, 2008·Clinical and Experimental Nephrology·Takeo KosakaMototsugu Oya
Mar 23, 2011·Expert Opinion on Biological Therapy·Scott S TykodiJohn A Thompson
Mar 18, 2010·The American Journal of the Medical Sciences·Nandakumar SrinivasanWaqar Ahmad
Sep 12, 2006·Urologic Oncology·Maryam AalamianDaniel L Levey
Jun 21, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Brian I RiniUNKNOWN Southwestern Oncology Group
Jan 16, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Brenda M SandmaierRichard W Childs
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kazutaka NakayamaNaoto T Ueno
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C Yang, Richard Childs
Dec 13, 2005·Expert Review of Anticancer Therapy·Robert O Dillman
Sep 6, 2006·Bone Marrow Transplantation·M BregniR Childs
Nov 4, 2006·Cancer·Ellen A RonnenRobert J Motzer
Mar 31, 2010·Clinical Journal of Oncology Nursing·Hollie DevineKathleen McDermott
Oct 31, 2006·Expert Review of Anticancer Therapy·Rodolfo PassalacquaMatteo Dalla Chiesa
Oct 31, 2006·Expert Review of Anticancer Therapy·Jan RoigasGero Massenkeil
Jun 29, 2011·Expert Review of Anticancer Therapy·Marco BregniUNKNOWN Solid Tumor Working Party of EBMT
Sep 14, 2007·Annals of Medicine·Michael Y ShapiraShimon Slavin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.